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Abstract
Background: Alterations in methylation patterns, miRNA expression, and stem cell protein expression occur in germ cell
tumors (GCTs). Our goal is to integrate molecular data across platforms to identify molecular signatures in the three main
histologic subtypes of Type I and Type II GCTs (yolk sac tumor (YST), germinoma, and teratoma).
Methods: We included 39 GCTs and 7 paired adjacent tissue samples in the current analysis. Molecular data available for
analysis include DNA methylation data (Illumina GoldenGate Cancer Methylation Panel I), miRNA expression (NanoString
nCounter miRNA platform), and stem cell factor expression (SABiosciences Human Embryonic Stem Cell Array). We
evaluated the cross platform correlations of the data features using the Maximum Information Coefficient (MIC).
Results: In analyses of individual datasets, differences were observed by tumor histology. Germinomas had higher
expression of transcription factors maintaining stemness, while YSTs had higher expression of cytokines, endoderm and
endothelial markers. We also observed differences in miRNA expression, with miR-371-5p, miR-122, miR-302a, miR-302d,
and miR-373 showing elevated expression in one or more histologic subtypes. Using the MIC, we identified correlations
across the data features, including six major hubs with higher expression in YST (LEFTY1, LEFTY2, miR302b, miR302a, miR
126, and miR 122) compared with other GCT.
Conclusions: While prognosis for GCTs is overall favorable, many patients experience resistance to chemotherapy, relapse
and/or long term adverse health effects following treatment. Targeted therapies, based on integrated analyses of
molecular tumor data such as that presented here, may provide a way to secure high cure rates while reducing
unintended health consequences.
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Background
Germ cell tumors (GCTs) include germinomas, com-
prised of testicular seminomas and ovarian dysgermino-
mas, and nonseminomas, comprised of yolk sac tumors
(YSTs), teratomas and embryonal carcinoma [1]. While
GCTs are heterogeneous, they are grouped together due
to a presumed common stem cell of origin, the
primordial germ cell (PGC). Oosterhuis and Looijenga
have proposed classification of GCTs into five distinct
entities based on cell of origin, histology, genomic im-
printing status, age at and location of clinical presenta-
tion, and chromosomal constitution [2]. Type I GCTs
are those found predominantly in infants and young
children, often manifesting in the first four years of life
and always before puberty. Type II GCTs are most com-
monly found in the testis of adolescent males and young
men following puberty, but are also found in the ovaries
of adolescent and young adult women and the midline/
brain of children and adolescents. Pathologic evidence
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confirms that GCTs are the neoplastic counterpart of
the PGC [2], and several lines of evidence indicate that
GCTs, including adult testicular GCT (TGCT), begin in
utero [3]. Thus, alterations in normal embryonic devel-
opment are likely to be etiologically relevant to GCTs.
Of particular interest are the processes the PGCs
undergo during normal development, including segrega-
tion from the somatic cells, migration to the gonads,
complete epigenetic reprogramming, reacquisition of
pluripotency and sex determination [4].
Aberrant DNA methylation has been implicated in
cancer etiology, and may be especially relevant in GCTs
due to the extensive epigenetic reprogramming that oc-
curs in the germ line and early embryo during normal
development [5]. Adult TGCTs have been studied most
thoroughly in the context of DNA methylation, and thus
a majority of our knowledge regarding methylation is
limited to these tumors. Interestingly, methylation pat-
terns in GCT differ by histologic subtype in both adults
and children [6–16]. In general, methylation increases
with tumor differentiation: the lowest levels of methyla-
tion occur in the embryonal carcinomas and the highest
in the teratomas [6, 7, 10, 11, 13, 15–18]. Understanding
methylation patterns in GCTs, overall and by histologic
type, may identify the developmental stage at which the
tumor arose. This knowledge in turn may identify the
at-risk period when external exposures are most
harmful.
MicroRNAs (miRNAs) are small endogenous noncod-
ing RNAs that regulate gene function in a manner spe-
cific to cell type and developmental stage [19–23].
Differential miRNA expression is associated with human
cancers [24–28], including GCTs in children and adults
[29–35]. These studies have reported higher expression
of miRNAs in the miR-371–73 and the miR-302 clusters
and lower expression of let-7 in Type I and Type II
GCTs compared to normal samples [29–37]. Alterations
in the serum levels of the miR371–3 and miR-302/367
MiRNAs also show promise as a diagnostic and follow-
up tool for TGCT patients [38], highlighting the poten-
tial translational impact of molecular evaluation.
Knowledge of stem cell biology is directly relevant to
mechanisms of GCT tumor initiation, maintenance and
metastasis, since reacquisition of pluripotency is a key
step in early germ cell development [39]. Typically, ex-
pression of stem cell markers (e.g., OCT3/4, STELLAR,
NANOG, LIN28) is induced following demethylation of
early stage germ cells [6, 17] and is turned off following
entry to meiosis [40–42]. Expression of pluripotency
markers past the appropriate developmental stage is a
hypothesized explanation for tumorigenesis in germ cells
[41]. Notably, studies of adult TGCT have shown aber-
rant expression of stem cell markers in intratubular
germ cell neoplasia (IGCNU), the precursor of TGCT,
and in undifferentiated histologic subtypes of GCTs
(seminomas and embryonal carcinomas) [43, 44]. Stem
cell markers are also expressed in early germ cells in fe-
males [45–47] and have been detected in ovarian dysger-
minomas [48]. Marker expression past the appropriate
developmental stage is correlated with genetic variation,
including mutation in c-KIT [48] and its ligand (KITLG)
[49], and DNA methylation [41]. Given that pediatric
GCTs likely originate from a germ cell at an earlier stage
of development than adult TGCTs [2], stem cell marker
expression may be particularly relevant in pediatric
tumors.
As described above, previous studies have described
variation in methylation, miRNA, and mRNA expression
in Type I and Type II GCTs, including studies that have
evaluated the interaction between miRNA and mRNA
expression [29, 35]. To further explore relevant molecu-
lar interactions, we used an integrated approach to
understand differences in promoter methylation, miRNA
expression, stem cell gene expression, and genotype data
by tumor characteristics in a series of GCTs. We evalu-
ated correlations between data based on the assumption
that these processes are linked and co-regulated (for ex-
ample, epigenetic changes within promoter regions and
expression of cognate miRNA species determine the
level of mRNA). We also find differences in miRNA ex-




Type I and Type II GCT samples from males and fe-
males were obtained from the Cooperative Human Tis-
sue Network (Columbus, OH). Tumors were resected at
initial diagnosis and snap frozen at −70 °C. Pathology re-
ports were also provided. Data were available for tumor
histology (YST, teratoma, germinoma, or mixed/other),
tumor location (gonadal or extragonadal), sex, and age
at diagnosis (< 10 years, ≥ 10 years). The age categories
were chosen based on tumor histology. The majority of
the tumors diagnosed between the ages of 4 and 10 were
of similar histology to the Type I tumors while tumors
diagnosed after age 10 included histologic subtypes typ-
ically included in the Type II category. Normal adjacent
tissue was also available for seven of the tumors in our
case series.
This analysis used existing data with no personal iden-
tifiers; therefore, the study was deemed exempt from re-
view (category #4) by the Institutional Review Board of
the University of Minnesota.
DNA and RNA extraction
Genomic DNA was isolated from GCT tissue and paired
normal adjacent tissue (when available) using either the
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TRIzol® extraction method (Invitrogen Life Technolo-
gies, California) or a QIAamp DNA Mini Kit (Qiagen
Sciences, Maryland) according to the manufacturer’s rec-
ommended protocol. DNA yield was quantified using
1 μl DNA on a NanoDrop™ spectrophotometer (Thermo
Scientific, Maryland). Extracted DNA was stored at
−80 °C until further analysis.
Total RNA was extracted from fresh frozen tissue
using the TRIzol® extraction method (Invitrogen Life
Technologies, California) according to the manufactur-
er's protocol. Following extraction, RNA was cleaned
using the RNeasy Mini Kit (Qiagen, Maryland) according
to the manufacturer's recommended protocol. RNA yield
was then quantified using 2 μl on a NanoDrop™ spectro-
photometer (Thermo Scientific, Maryland). Extracted
RNA was stored at -80O C until further analysis.
Methylation analysis
DNA methylation was measured as previously described
[16]. Briefly, prior to methylation analysis, 1 μg genomic
DNA was treated with sodium bisulfite to convert
unmethylated cytosines to uracil using the EZ DNA
Methylation Kit (Zymo Research, Orange, CA) according
to manufacturer’s protocol. DNA methylation at 1505
CpG loci in 807 cancer-related genes was evaluated
using the GoldenGate Cancer Methylation Panel I (Illu-
mina, Inc.) in the University of Minnesota Genomics
Center following the manufacturer’s protocol as de-
scribed [50]. Replicates were included, including four
duplicates that were included on both arrays and five
duplicates that were included within one array.
Methylation was calculated as the variable β, which is
the ratio of the fluorescent signal from the methylated
allele to the sum of the fluorescent signals of both meth-
ylated and unmethylated alleles [50]. GenomeStudio
software (Illumina, Inc) was used to calculate the aver-
age methylation values (β) from the ~30 replicate methy-
lation measurements for each CpG locus. We used raw
average β values without normalization. GenomeStudio
software was also used to assess data quality for each
CpG loci. We omitted all CpG loci where ≥ 25 % of the
samples had a detection p-value > 0.05 (N = 16, 1 %). X-
linked CpG loci (N = 84) were also removed, resulting in
1,405 loci for analysis.
miRNA expression
Expression of 800 miRNAs was measured using the
NanoString nCounter miRNA Expression Assay kit
(NanoString Technologies, Seattle, WA). The nCounter
detects total counts of miRNA through hybridization
with fluorescently labeled bar coded probes to the miR-
NAs of interest followed by scanning and counting to
quantify expression [51]. Total RNA samples were ana-
lyzed following the manufacturer’s instructions for the
Human v2 miRNA Expression Assay Kit (NanoString
Technologies, Seattle, WA).
Stem cell factor expression
Real-time quantitative PCR gene expression profiling
was performed for 84 pathway-specific genes using the
human Embryonic Stem Cells RT2 Profiler PCR Array
according to the manufacturer’s protocol (SABios-
ciences, Frederick, MD). Briefly, the RT2 First Strand Kit
(SABioscience, Frederick, MD) was used to synthesize
cDNA from 1 μg purified RNA. cDNA was obtained
with a High Capacity cDNA Reverse Transcription Kit
(Applied Biosystems, Foster City, CA), and quantitative
PCR (qPCR) was performed with a StepOnePlus Real-
Time PCR system (Applied Biosystems, Foster City,
CA). Expression of all genes was normalized to average
expression of five endogenous housekeeping genes
(E2M, HPRT1, RPL13A, GAPDH, and ACTB).
Genotyping
Genotype data were generated for four SNPs identified
in GWAS of adult TGCT as previously described [52].
Briefly, PCR amplification and sequencing were per-
formed for SNPs in three genes: SPRY4 (rs4324715),
BAK1 (rs210138) and DMRT1 (rs755383). The KITLG
(rs4474514) SNP was detected using a made-to-order
TaqMan® SNP Genotyping Assay from Applied Biosys-
tems Inc (catalog# 4351379, assay# C_26154778_10).




We used NanoStriDE for normalization and differential
expression analysis of the miRNA data [53]. Positive
control normalization was conducted by creating a
normalization factor for each sample using the 6 positive
assay controls on the array and negative control
normalization was conducted as an upper quantile ap-
proach as recommended by the manufacturer (Nano-
String Technologies, Seattle, WA). Discrete count data
were compared across demographic and tumor charac-
teristics using a negative binomial distribution as de-
scribed by Anders and Huber [54]. We included a
Benjamini-Hochberg correction for multiple compari-
sons [55].
Stem cell factor expression analysis
Raw gene expression values were normalized to endogen-
ous housekeeping genes prior to statistical analyses. Un-
supervised hierarchical clustering was conducted using the
matrix visualization and analysis platform Gene-E with the
city block metric and average linkage [56]. Fold change of
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gene expression was determined using the 2(−ΔΔCt) method,
and compared YST (n = 9) to germinomas (n = 8).
Cross platform analysis
Patient age and sex, tumor location (ovary, testis, and
extragonadal), and histology (normal adjacent, teratoma,
dysgerminoma, YST and mixed) data were combined
with molecular data across a common set of 40 samples
into a single two-dimensional matrix. Categorical pheno-
type and genotype values were arranged in a logical
manner (e.g., low severity to high severity for tumor hist-
ology) and assigned a numerical code that could be used
for correlation analysis. These data were combined with
the β values from the methylation analysis, the miRNA
counts, and the normalized ΔCt values from the SABios-
ciences Embryonic Stem Cell array. Additionally, geno-
types for the four molecular markers listed above were
encoded based on the Kimura matrix [57] idea that tran-
sitions are more likely than transversions and hence
grouped together where possible.: −4.0 = t/t; −3.0 = c/t;
−2.0 = c/c; −0.5 = g/t; −0.2 = c/g; 0.2 = a/t; 0.5 = a/c; 2.0 =
a/a; 3.0 = a/g; 4.0 = g/g.
Two types of correlations were explored using the vec-
tor of values for each matrix row (i.e., molecular probe
or phenotypic label) against the corresponding vector of
values for each of the other rows: standard linear corre-
lations using the Pearson correlation coefficient and
more complex nonlinear correlations using the Maximal
Information Coefficient (MIC) [58]. MIC analysis was
performed using the R implementation of the MINE
software package (http://www.exploredata.net/). This re-
sulted in two values for correlation (linear, nonlinear) for
every pairwise combination of molecular probes and/or
phenotypic variables. This very large result matrix was
filtered to retain only those pairs that represented a
comparison across platforms (or between a phenotypic
variable and a platform) and whose Pearson correlation
or MIC values exceeded a threshold of 0.75. This thresh-
old was chosen as it provided a compromise between
very dense graph connectivity at lower thresholds and
sparse connectivity at high cutoffs.
The resulting pairwise correlations were visualized as a
network using Gephi software (https://gephi.org/). In
order to visualize the correlation networks, the molecu-
lar probes and phenotypic variables served as nodes in
the network graph, and an edge was drawn between any
nodes that had either a linear or nonlinear correlation
that exceeded 0.75. The edge was labeled with the larger
of either the Pearson R-value or the MIC. These data
were loaded into Gephi, and the Force Atlas 2 layout
was executed, running until the nodes were far separated
in apparent equilibrium, and then the Fruchterman
Reingold layout was selected. All pairwise correlations
were grouped by single linkage clustering to create
networks. Network hubs with four or more neighbors
were identified.
The hub nodes and their nearest neighbors were
concatenated into a list, and the standard gene symbols
extracted. These gene symbols were uploaded to Ingenu-
ity Pathway Analysis software (IPA, http://www.ingenui-
ty.com/products/ipa), and investigated for upstream
activators. To guard against the possibility that func-
tional categories were identified by chance due to the a
priori bias in the initial set of profiling molecules, we
randomly selected three additional sets of the same size
from the same initial profiling molecules, and submitted
these random gene lists to IPA.
The entire analysis process was repeated using subsets
of the data. In the entire data set of 40 samples with
complete genomic data, it was noted via manual analysis
of scatterplots of primary hub genes that differences in
the 8 YSTs relative to the other samples dominated the
signal. Following the assumption that the YSTs were
overshadowing any signal from other histology types, we
tested a subset consisting of the 32 non-YST samples.
Results
Characteristics of the study samples
Tumor specimens from 38 cases of Type I and Type II
GCT ranging in age from 0 to 21 years were included in
this analysis, including 9 YSTs, 18 teratomas, 7 dysger-
minomas, and 4 with mixed histology (Table 1). In
addition, one dysgerminoma from a 45 year old woman
(Type II GCT) was included because it had similar
methylation, miRNA and stem cell factor expression
values as the adolescent dysgerminoma samples. The
YSTs were evenly distributed among boys and girls while
the majority of cases with a germinoma or teratoma
were female. Information on race/ethnicity was not
available for the cases.
The four cases with mixed histology all had a teratoma
component of the tumor. The three tumors in male cases
also had YST. One mixed tumor in an adolescent male
and the tumor in an adolescent female also had compo-
nents of embryonal carcinoma and choriocarcinoma. Nor-
mal adjacent DNA was available for seven cases. The
seven normal adjacent tissue samples included four ovary
or fallopian tube tissues, one testis tissue, one adjacent
lymph node and one thymus tissue. The testis sample was
from a one year old case and is unlikely to contain
IGCNU. Results from methylation and genotyping data
have been previously published [16, 52]. and are therefore
not included in this report.
miRNA expression
In a comparison across all histologic subtypes, we ob-
served significant differences in miRNA expression for
five miRNA species (Fig. 1). Of these, all had low
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expression in normal adjacent tissue. One miRNA was
elevated only in dysgerminomas (hsa-miR-371–5p). The
other four miRNAs were elevated in YST with varying
expression differences in other histologic subtypes. We
did not observe differential expression for any miRNA
species when we compared gonadal vs. extragonadal tu-
mors, tumors from males vs. females, or tumors from
children diagnosed prior to age 10 years vs. those diag-
nosed at or after 10 years of age (data not shown).
Stem cell factor expression
Unsupervised hierarchical clustering based on tumor hist-
ology highlights differences in the expression of stem cell
genes by tumor histology (Fig. 2a), with the YST and dys-
germinoma separating into distinct clusters, while the
teratomas (mature and immature) and normal adjacent
tissue clustered together. Mixed GCTs were interspersed
throughout the groups. To better understand the expres-
sion differences in YST and dysgerminoma, we compared
relative expression of each gene in these two groups. Of
the 84 genes included in the array, 40 had a statistically
significant up- or down-regulation in YST compared with
dysgerminoma (p < 0.05). When these genes were catego-
rized by function in pathways regulating initiation and
maintenance of cellular stemness, we noted distinct pat-
terns based on tumor histology (Fig. 2b). For example,
transcription factors related to stemness had higher ex-
pression in dysgerminomas, while endoderm, trophoblast,
and mesoderm markers had higher expression in YST.
Cross-platform Analysis
We observed 760 cross-platform correlations that exceed-
ing our threshold of 0.75 for either the Pearson correlation
coefficient or the MIC. When these data correlations were
Table 1 Selected characteristics of the study population
Yolk Sac Tumor Dysgerminoma Teratoma Mixed/Other Normal
N (%) N (%) N (%) N (%) N (%)
Age (years)
Median (range) 1 (0–19) 13.5 (7–45) 4.5 (0–21) 10 (0–14) 11 (1–19)
Sex
Male 5 (56) 0 3 (17) 3 (75) 2 (29)
Female 4 (44) 8 (100) 15 (83) 1 (25) 5 (71)
Location
Ovary 2 (22) 8 (100) 9 (50) 1 (25) 1 (14)
Testis 2 (22) 0 1 (5.6) 2 (50) 1 (14)
Extragonadal 5 (56) 0 8 (42) 1 (25) 5 (71)
Fig. 1 miRNA expression by tumor histology. Five miRNA species had significant expression differences by tumor histology (q-value < 0.05). Three
samples were excluded due to missing or poor quality miRNA data (1 YST, 1 mixed/other, and 1 normal adjacent)
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visualized, six network hubs were identified (Fig. 3),
including the miRNAs, miR-122, −126, −302a and
-302b and the stem cell genes, LEFTY1 and LEFTY2.
These changes were influenced largely by differences
in the expression in YST vs. tumors of other histo-
logic subtypes. In order to detect differences that may
have been overshadowed by the strong influence of
the YSTs, we also repeated the analysis including only
the dysgerminomas and teratomas. In this analysis,
the protein T (brachyury) was identified as a network
hub linking a large number of molecular features
(data not shown).
Using IPA, we identified many predicted upstream
activators that were enriched in the list of genes
with large cross platform correlations (N = 45 genes).
After comparison with the p-values from the ran-
domly selected gene lists, there were three molecules
(TP73, decitabine, and tretinoin) with statistically
significant p-values after Benjamini-Hochberg correc-
tion, suggesting that these molecules are promising
upstream activators.
Discussion
In this analysis, we used a novel method to integrate
molecular data across platforms to gain biological
insight into the function of GCTs. These analyses
highlighted several network hubs, including miRNA
clusters and stem cell genes that distinguish YST from
normal germ cell samples and other GCTs. Import-
antly, our approach confirmed several previously re-
ported alterations in embryonic stem cell specific
miRNAs. Finally, our analysis of stem cell factor ex-
pression highlights the altered expression of multiple
stem cell genes in GCTs, with distinct patterns in
YST and dysgerminoma. Collectively, these findings
suggest that ectopic, aberrant expression of stem cell
genes may underlie the unusual and defining capacity
of self-renewal in the face of wide differentiation into
cells with characteristics of tissues derived from any
of the three germ layers observed in GCT, and it is
possible that higher levels of stem cell gene expres-
sion correlate with tumor progression and prognosis
of GCT and other tumors.
Fig. 2 Stem cell expression by tumor histology. a Unsupervised hierarchical clustering analysis of normalized ΔCt values. Blue indicates high levels of
expression and red indicates low levels of expression. The mixed tumor that clustered with the teratomas rather than the other mixed tumors included
components of teratoma and YST. b Genes with≥ 3 fold (log2 fold > 1.58) up- or down-regulation in YST compared with germinoma. Bar color represents
gene pathway. Four samples were excluded due to missing data (1 YST, 1 teratoma, and 2 normal adjacent)
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Our findings are consistent with previous studies of
Type I and Type II GCTs that have identified an overex-
pression of the miR-371–73 and miR-302 clusters in
GCTs compared with normal samples [29–35]. The
miRNA-302 and miRNA-371–373 clusters are highly
plausible candidate miRNAs in GCTs given their roles
as regulators of embryonic stem cell pluripotency
markers [59, 60] which has been discussed extensively in
previous miRNA expression studies of GCTs [33, 35].
Pinpointing the relevant targets of miRNA can be daunt-
ing given the large number of target proteins for each
miRNA. According to the online database for miRNA
target prediction and functional annotations, miRDB
[61, 62] the number of predicted targets for miRNAs in
the miR-371–373 and miR-302 families range from 469
to 529; interestingly, LATS2 is one of the highest rank-
ing targets on the list for all miR-302 family members as
well as miR-372 and miR-373 (Target Score > 98) [62].
Functional studies have demonstrated that miRNA-372
and miRNA-373 act as oncogenes in TGCT through in-
teractions with the p53 pathway, in particular through
regulation of LATS2 [32]. Bioinformatic algorithms indi-
cated that miRNA expression in these clusters is associ-
ated with downregulation of mRNA expression in other
pathways with biological relevance to GCT [33, 35].
Data also suggest that the miRNA 302 family can be
Fig. 3 Visualization of cross-platform correlations using Gephi. 760 cross-platform correlations had a Pearson correlation or a MIC that exceeded a threshold
of 0.75. Network visualization via Gephi identified five network hubs (>4 nearest neighbors) that differentiated YST from the other histologic subtypes.
Seven samples were excluded because they did not have complete data for methylation, miRNA, stem cell gene expression (2 YST, 1 teratoma, 1 mixed/
other, and 3 normal adjacent)
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used to reprogram cancer cells into pluripotent cells
with an ES cell-like phenotype [63]. Collectively, these
data suggest that these miRNA clusters are in large part
responsible for regulating the stem cell phenotype of
GCTs.
Four of the six hubs identified in the cross-platform
analysis were stem cell related, and highlight the import-
ance of the transforming growth factor (TGF)-β super-
family members in GCT development. Specifically, the
miR-302 cluster regulates the Nodal inhibitors LEFTY1
and LEFTY2 [64]. This interaction plays an important
role in germ layer specification by promoting the forma-
tion of the mesendodermal lineage while suppressing
neuroectorderm formation [65]. Knockdown of either
protein in mice results in altered differentiation, with
Lefty1 knockdown leading to increased differentiation
potential and Lefty2 knockdown leading to increased im-
mature neuroepithelium [66]. This pathway also plays
other important roles in germ cell development, includ-
ing regulating meiosis in the male germ cells [67, 68]. Fi-
nally, the nodal signaling pathway regulates the bone
morphogenic protein pluripotency pathway [69], which
was previously shown to play an important role in the
development of GCT [70]. The importance of miR-122
and miR-126 in GCT is less clear and will require fur-
ther study. Interestingly, miR-122 was also overex-
pressed in YST compared with germinoma and normal
gonad tissue in a previous study of miRNA in GCT [33].
Notably, none of the methylation differences that were
so striking in our comparison of YST to other GCTs
[16] were identified as being hubs in the cross-platform
analysis, suggesting that these changes may be conse-
quence of the altered expression of stem cell genes and
miRNAs rather than drivers of the oncogenic process.
Given that the associations between the four SNPs eval-
uated did not differ by tumor histology [52, 71, 72], it
was not as surprising that none of these were identified
as hubs in the comparison of tumors by histology.
We chose to use platforms that were highly enriched
for cancer and stem cell genes due to the higher infor-
mation yield when compared to an unbiased search;
however, this limited our ability to conduct an unbiased
search for over-represented gene categories in the list of
features with high cross-platform correlations. We were
able to evaluate upstream regulators of these highly cor-
related features, and we identified three highly enriched
activators (TP73, Tretinoin, and Decitabine) in the set of
hub-connected genes in the entire dataset. Given the
known importance of retinoic acid in germ cell develop-
ment [73], it is not surprising that Tretinoin, a topical
retinoid, would be identified as a potential regulator
in GCTs. The DNA hypomethylating agent Decitabine
(5-aza-2’-deoxycytidine or 5-aza) is also intriguing as a
potential therapy given relevant data in the literature.
Decitabine is effective for treatment of hematologic
malignancies [74, 75] and has also been evaluated in
studies of solid tumors with varying success rates
[76]. Preclinical data suggesting that hypomethylating
agents may re-sensitize cells to platinum based
chemotherapy [77–79] are of particular relevance for
GCT; however, early phase clinical trials in epithelial
ovarian cancer have provided mixed results of the
combination of decitabine and carboplatinum [80–82].
In a previous study of embryonal carcinoma, high
expression of the pluripotency-associated DNA methyl-
transferase 3B (DNMT3B) was associated with sensitivity
to 5-Aza [77, 83]. The elevated expression of DNMT3B
in YST observed here and in a previous DNA methylation
study [15] suggests that this may also be a relevant alter-
native therapy for YST, which often have poorer outcomes
than other histologic subtypes [84].
Most cancers are heterogeneous and multifactorial
[85]. This complexity stems from molecular events on
the level of gene integrity, epigenetic modification and
transcription, stability of mRNA transcripts (e.g., by
miRNAs), translation, protein activation (e.g., by phos-
phorylation), and cellular interactions, including within
the tumor microenvironment. Because of this complex-
ity, it is important to evaluate the joint effects of these
alterations. There is not one clear method for evaluating
these complex interactions on large datasets. In this ana-
lysis, we chose to utilize the MIC as a tool to evaluate
the correlations in the dataset in addition to simple lin-
ear Pearson correlation. MIC is able to detect linear rela-
tionships and correlations among variables that are not
strictly linear (such as quadratic or oscillatory associa-
tions). Care should be taken when using the MIC with
small datasets (e.g., N < 30), as it may identify spurious
correlations in this extreme [86]. Also, despite a recent
debate [87] as to which information-theory based meas-
ure provides the highest statistical power (maximal in-
formation coefficient or a related measure, mutual
information), both measures clearly identify nonlinear
trends that are missed by Pearson correlation. Addition-
ally, our analysis included a small number of samples
which could have limited our power to detect relevant
associations. Finally, our analysis focused on a selected
list of genes with a priori significance in cancer and stem
cells. It is possible that a genome-wide, agnostic ap-
proach would identify additional relevant characteristics
of GCTs in additional pathways.
Conclusions
Our analysis suggests that the stem cell phenotype of
GCTs is a defining characteristic of GCTs, especially in
YSTs. While prognosis for GCTs is overall favorable,
subgroups of patients experience resistance to chemo-
therapy and/or high rates of relapse [88–90]. In addition,
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the nonspecific and highly cytotoxic chemotherapy used
can cause many adverse health effects including cardio-
vascular disease, hearing loss, and second cancers [91–
95]. Targeted therapies, based on integrated analyses of
molecular tumor data such as that presented here, may
provide a way to improve cure rates in the subgroup of
patients who fail to respond to current therapies and
may also provide an opportunity to reduce the unin-
tended health consequences associated with current che-
motherapeutic agents.
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